Pulse Biosciences完成Precise-Btn临床研究入组，评估Npulse™ Vybrance™经皮电极系统治疗症状性良性甲状腺结节

美股速递09-15

Pulse Biosciences已顺利完成Precise-Btn临床研究的全部患者入组工作。该研究旨在评估其Npulse™ Vybrance™经皮电极系统对于症状性良性甲状腺结节的疗效与安全性。

这一里程碑式的进展，标志着该公司在推进这一创新型治疗方案的进程中迈出了关键一步。通过该系统，医生有望为那些饱受良性甲状腺结节困扰的患者提供一种非手术的替代治疗选择。

此次入组工作的圆满完成，为后续的数据收集与分析奠定了坚实基础。业界普遍关注该研究最终能否验证这一技术的临床价值，从而为甲状腺结节的治疗领域带来革新性的突破。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/1132194139?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-09-15 19:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1132194139","market":"us","top_or_hot":-1,"title":"Pulse Biosciences完成Precise-Btn临床研究入组，评估Npulse™ Vybrance™经皮电极系统治疗症状性良性甲状腺结节","media":"美股速递","content":"<p>Pulse Biosciences已顺利完成Precise-Btn临床研究的全部患者入组工作。该研究旨在评估其Npulse™ Vybrance™经皮电极系统对于症状性良性甲状腺结节的疗效与安全性。</p>\n<p>这一里程碑式的进展，标志着该公司在推进这一创新型治疗方案的进程中迈出了关键一步。通过该系统，医生有望为那些饱受良性甲状腺结节困扰的患者提供一种非手术的替代治疗选择。</p>\n<p>此次入组工作的圆满完成，为后续的数据收集与分析奠定了坚实基础。业界普遍关注该研究最终能否验证这一技术的临床价值，从而为甲状腺结节的治疗领域带来革新性的突破。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pulse Biosciences完成Precise-Btn临床研究入组，评估Npulse™ Vybrance™经皮电极系统治疗症状性良性甲状腺结节</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPulse Biosciences完成Precise-Btn临床研究入组，评估Npulse™ Vybrance™经皮电极系统治疗症状性良性甲状腺结节\n</h2>\n\n<h4 class=\"meta\">\n\n2026-09-15 19:01 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pulse Biosciences已顺利完成Precise-Btn临床研究的全部患者入组工作。该研究旨在评估其Npulse™ Vybrance™经皮电极系统对于症状性良性甲状腺结节的疗效与安全性。\n这一里程碑式的进展，标志着该公司在推进这一创新型治疗方案的进程中迈出了关键一步。通过该系统，医生有望为那些饱受良性甲状腺结节困扰的患者提供一种非手术的替代治疗选择。\n此次入组工作的圆满完成，为后续的数据...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PLSE","symbol_name":"Pulse Biosciences, Inc.","start_time":0,"source_url":"","article_id":"1132194139","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1132194139","pubTimestamp":1789470082,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Pulse Biosciences已顺利完成Precise-Btn临床研究的全部患者入组工作。该研究旨在评估其Npulse™ Vybrance™经皮电极系统对于症状性良性甲状腺结节的疗效与安全性。\n这一里程碑式的进展，标志着该公司在推进这一创新型治疗方案的进程中迈出了关键一步。通过该系统，医生有望为那些饱受良性甲状腺结节困扰的患者提供一种非手术的替代治疗选择。\n此次入组工作的圆满完成，为后续的数据收集与分析奠定了坚实基础。业界普遍关注该研究最终能否验证这一技术的临床价值，从而为甲状腺结节的治疗领域带来革新性的突破。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"PLSE":"Pulse Biosciences, Inc.","BK4082":"医疗保健设备"},"translate_title":"Pulse Biosciences completes enrollment in Precise-Btn clinical study to evaluate Npulse ™ chosen ™ Treatment of symptomatic benign thyroid nodules with percutaneous electrode system","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PLSE":1},"content_text":"Pulse Biosciences已顺利完成Precise-Btn临床研究的全部患者入组工作。该研究旨在评估其Npulse™ Vybrance™经皮电极系统对于症状性良性甲状腺结节的疗效与安全性。\n这一里程碑式的进展，标志着该公司在推进这一创新型治疗方案的进程中迈出了关键一步。通过该系统，医生有望为那些饱受良性甲状腺结节困扰的患者提供一种非手术的替代治疗选择。\n此次入组工作的圆满完成，为后续的数据收集与分析奠定了坚实基础。业界普遍关注该研究最终能否验证这一技术的临床价值，从而为甲状腺结节的治疗领域带来革新性的突破。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1132194139","isCrawlerRequest":true}